A combined blockade of V-domain Ig suppressor of T-cell activation (VISTA) and PD-1 is a promising new cancer treatment option, which was efficient in murine tumor models and is currently tested in first phase I studies. Here, we analyzed the VISTA expression in a large and well-characterized gastric cancer (GC) cohort on 464 therapy-naive GC samples and 14 corresponding liver metastases using immunohistochemistry. Staining results were correlated with clinico-pathological characteristics, genetic alterations and survival. VISTA expression in tumor cells was detected in 41 GCs (8.8%) and 2 corresponding liver metastases (14.3%). Moreover, VISTA expression in immune cells was observed in 388 GCs (83.6%) and 6 liver metastases (42.9%). VISTA expression was associated with the Laur en phenotype, tumor localization, Epstein-Barr virus infection, KRAS-and PIK3CA-mutational status and PD-L1 expression. There was no significant correlation with patient outcome. Moreover, a change of VISTA expression in immune cells during tumor progression was observed. The co-incidence of VISTA and PD-L1 expression indicates a dual immune evasion mechanism of GC tumor cells and makes GC an interesting target for novel combined immune checkpoint inhibitor treatments.
Introduction
Cancer immunotherapy that targets immune checkpoints is a promising new treatment option in several tumor entities and is currently developing in a breathtaking speed. In gastric cancer (GC), targeting of the immune checkpoint pathways such as cytotoxic T-lymphocyte associated protein-4 (CTLA4), programmed cell death protein-1 (PD-1) and its ligand PD-L1 is currently investigated extensively in several clinical trials. 1 GC is a heterogeneous disease with a marked genetic complexity that has been recently shown in an integrative genomic analysis including whole-genome sequencing. A molecular classification was proposed, which categorizes four subtypes, i.e., EpsteinBarr-virus-associated (EBVa), microsatellite instable (MSI), chromosomal instable (CIN) and genomically stable (GS) GCs. 2, 3 Two of the four molecular subtypes, EBVa and MSI GC, are significantly associated with an increased PD-L1 expression and are thereby suggested to be particular suitable for an immune checkpoint therapy. 4 Moreover, MSI GCs are characterized by a highmutational load, which is associated with a better response to anti-PD-1/PD-L1 immune checkpoint therapies in several tumor entities. 5 Nevertheless, all kind of tumors, including microsatellite stable and EBV-negative GCs, need strategies to evade immune attacks. 6 This leads to the conjecture that malignant tumors apply additional or supplementary immune escape mechanisms.
V-domain Ig suppressor of T-cell activation (VISTA), also known as PD1 homolog (PD1H), C10orf54 or Dies1, belongs to the B7 family. VISTA encodes for a type I membrane protein and is expressed predominantly on hematopoetic cells, e.g., myeloid, granulocytic and T cells. 7 Although the exact VISTA binding partners are not yet known, several studies have demonstrated that VISTA serves both as a ligand (for antigen presenting cells) and as a receptor (for T cells), and that VISTA suppresses T-cell activation. In murine tumor models, anti-VISTA monoclonal antibodies (mAbs) lead to an increased number and elevated function of intratumoral T cells and thereby boost antitumor immunity.
Results
A total of 464 patients fulfilled all study criteria. The clinicopathological characteristics of our patient cohort are summarized in Table 1 . Tumor-specific survival data was available in 422 cases (90.9%). Mean follow-up period was 37.8 mo (range 0.2-135.3 mo).
VISTA expression
VISTA expression was observed in tumor, immune and endothelial cells, but not in nonneoplastic gastric epithelium. A total of 41 out of 464 cases (8.8%) showed a VISTA expression in tumor cells, which was exclusively cytoplasmatic. The percentage of stained tumor cells ranged from 0% to 90% (median 0%), the staining intensity ranged from negative (0) to strong (3; median 0; Fig. 1A-C) . In cases of different staining intensities within the same tumor, only the highest intensity was indicated. Although we aimed for the HistoScore, 11 we recognized that the overall percentage of VISTA-positive tumor cells was mainly low (in 73.2% of the cases 10% positive tumor cells) and assessment of different percentages of three different staining intensities was indiscernible and impractical.
The overall number of intratumoral immune cells per mm tumor localization: Pairwise testing demonstrated that VISTA was detected significantly more often in intestinal (p D 0.001 for VISTA expression in tumor cells; p < 0.001 for VISTA expression in immune cells) and unclassified GCs (p D 0.019 for VISTA expression in tumor cells; p < 0.001 for VISTA expression in immune cells) than in diffuse GCs, and significantly more often in GCs of the proximal than the distal stomach, respectively. Moreover, VISTA expression in immune cells was associated with the KRASand PIK3CA-mutational status: A high VISTA expression in immune cells was observed significantly more often in KRAS-and PIK3CA-mutant GCs (Table 1) .
There was no association between VISTA expression in tumor cells or immune cells and gender, age, mucin phenotype, tumor stage (T-category), lymph node metastases (N-category), distant metastases (M-category), presence of liver metastases, UICC stage, lymph node ratio, lymph vessel invasion (L-category), blood vessel invasion (V-category), resection status (Rstatus), Helicobacter pylori infection, Her2/neu-, MET-status, RHOA-or GNAS-mutations, or no PD-1 expression in immune cells (Tables 1 and S1 ).
Although there was no association between VISTA expression in immune cells and overall T-category, the amount of VISTA-positive immune cells significantly increased (p D 0.026) from category T1 to T2 and decreased thereafter (p D 0.016; Fig. 2) .
No association was found between the VISTA expression in endothelial cells and clinico-pathological patient characteristics (Table S2) .
VISTA expression in PD-L1-positive, EBVa and MSI GCs
As shown in a previous study, a high PD-L1 expression in tumor cells was observed significantly more often in EBVa and MSI GCs. 4 In this study, high VISTA expression in immune cells was observed significantly more often in GCs with high PD-L1 expression and in EBVa GCs (p < 0.001), but not MSI GCs. Moreover, VISTA expression in tumor cells was associated with PD-L1 expression in tumor cells (p D 0.002), but not with the EBV-status (p D 0.240) or with the MSI-status (p D 0.233): VISTA-expressing tumor cells were found in only one MSI GC, and VISTA expression in tumor cells and EBV-association was mutually exclusive (Fig. 3A and Table 1 ).
Prognostic significance
Patient prognosis significantly depended on the Laur en-phenotype, T-, N-, M-, L-, V-and R-category, UICC-stage, lymph node ratio, MSI-, MET-, PD-L1-(tumor and immune cells) and PD-1-status (immune cells; data not shown). There was no significant correlation between VISTA expression in any tumor component and patient survival (Tables 1 and S2 and Fig. 3B-D) .
Expression in liver metastases
Tissue specimens from liver metastases were available in 14 cases. Two metastases (14.3%) showed a cytoplasmatic VISTA expression in tumor cells, which accounted for 1-10%, respectively ( Fig. 1H and I) . Table S3 ). 
Discussion
This study is the first evaluation of VISTA expression in a large cohort of human tumors. All previous studies have been done in small series of human tumor specimens, cell lines or murine models, and many results of these former studies cannot be directly transferred one-to-one to human subjects without verification. Yet, human VISTA shares 90% homology with murine VISTA, and similar suppressive functions and expression patterns are reported for both variants.
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VISTA is known to serve both as a receptor and a ligand.
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Consistently with studies of murine models, in this study, VISTA was expressed in a substantial amount of immune cells. Additionally, a distinct cytoplasmatic VISTA expression in tumor cells was observed in a small subset of GCs. Interestingly, GCs with VISTA-positive tumor cells had the same clinicopathological characteristics like GCs with VISTA-positive immune cells, e.g., an intestinal phenotype and a proximal localization. One reason why VISTA expression in tumor cells was not found in a former GC cell line model of Oliveira et al.
14 might be its low frequency of 8%. Likewise, VISTA expression in GC tumor cells, most GC alterations apply to only a small subset of GCs. This necessitates validation studies on large cohorts. Moreover, it substantially aggravates the development of a personalized GC treatment. Hence, an appropriate case selection that considers tumor histology and intratumoral heterogeneity as well as other clinico-pathological characteristics is essential for a successful drug development, a practical testing and a reasonable therapy selection.
VISTA is expressed in GC and associated with PD-L1 expression
Although VISTA belongs to the B7 family, its functions are nonredundant with other Ig superfamily members. 7 In the present study, VISTA was significantly associated with PD-L1 expression. This might indicate that a subgroup of GCs seems to use a (at least) dual synergistic or successive VISTA/PD-L1/ PD-1 related mechanism to escape immunity. Moreover, it is a highly interesting observation regarding a combined VISTA/ PD-1 blockade as a new cancer treatment option.
It is well known that the composition of the immune cell infiltrates varies not only between different tumor entities, but also within tumors of the same anatomic site. Lines et al. predicted that a frank myeloid infiltrate in tumor lesions would express high levels of VISTA. 13 In this study, a high level of VISTA expressing immune cells was indeed observed in EBVa GCs, but not in MSI GCs, which are both characterized by a marked lymphoid infiltrate. Contrarily to PD-L1, VISTA expression in tumor cells was associated neither with MSI nor with EBV status. This indicates that, besides EBVa and MSI GCs, GCs with VISTA/PD-L1 co-expression might represent a third GC subgroup that could benefit from a targeted immune checkpoint inhibitor treatment. A high VISTA expression was observed more often in intestinal GCs, according to Laur en, GCs of the proximal stomach, KRAS-mutated GCs and, although without statistical significance, in Her2/neu-positive GCs. These four clinico-pathological characteristics are in turn significantly correlated with the molecular subgroup of CIN GCs, 2 which leads to the consideration that GCs with high VISTA expression might be assigned to CIN GCs. To confirm this presumption, a correlation between VISTA expression and other putative markers of chromosomal instability, e.g., TP53 mutations, should be evaluated.
Potential tumor biologic impact of VISTA expression in GC
VISTA expression in both immune cells and tumor cells was associated with the Laur en phenotype. A low VISTA expression was observed significantly more often in GCs with a diffuse phenotype according to Laur en, which is poorly differentiated and associated with a high recurrence rate and aggressive clinical behavior. The predominant expression of VISTA in intestinal GCs is in accordance with the finding that, apart from its immune modulating functions, VISTA is also known to be a regulator of differentiation. 15 Although there was no association between VISTA expression and tumor stage, lymph node metastases, distant metastases, or UICC stage, interestingly, the amount of VISTA-positive immune cells significantly increased from tumor category pT1 to pT2 and significantly decreased from pT2 to pT3. Thus, VISTA expression in immune cells and immune evasion changes during tumor progression and hallmarks an adaptive process of GC. The fact that this applies only to the tumor category but neither to nodal or distant metastases (N-/M-category) nor the UICC stage leads to the conjecture that VISTA expression rather influences the local tumor progression than the distant tumor spread. In this context, it is interesting to note that we have previously made the same observation for PD-L1 expression in tumor cells, which was high in pT2-tumors and lower in pT3 and pT4-tumors. Thus, GCs may apply different strategies of immune evasion (PD-1/PD-L1 and/or VISTA), which take place during the transition between tumor stage T2 and T3.
In contrast to PD-L1 and PD-1, VISTA expression was not correlated with patient survival. Hence, VISTA expression is unsuitable as a predictor of GC prognosis. On the other hand, the incoherence between VISTA expression and survival might be beneficial in the future interpretation of therapy effects of an anti-VISTA cancer therapy. The results are not expected to be biased by treatment independent effects.
VISTA is concordantly expressed in corresponding liver metastases
In patients with a metastatic and/or unresectable GC, diagnostic tissue specimens might, e.g., be obtained from liver metastases. For Her2/neu, a discordance rate between the primary GC and the liver metastasis ranging from 9% to 16% is known. 16 In our study, VISTA expression in liver metastases was observed in only a small portion, but concordant staining patterns with the primary tumor were found in the majority of cases. Yet, VISTApositive GCs had VISTA-negative liver metastases, and vice versa. Nevertheless, the presence of a VISTA expression in liver metastases alone is an interesting finding, which might be relevant for clinical trials regarding anti-VISTA immune checkpoint inhibitor treatment of metastatic disease.
Conclusion
Summing up, this is the first evaluation of VISTA expression in a large cohort of GC, and, moreover, the first description of VISTA expression in human tumor cells. We hereby show that VISTA expression changes during tumor progression. The coincidence of VISTA and PD-L1 expression in microsatellite stable and EBV negative GCs indicates a dual immune evasion mechanism and makes GC an interesting target for novel combined immune checkpoint inhibitor treatments. Further research in this field, including the impact of VISTA expression as a predictive biomarker, is urgently needed, and the results of ongoing anti-VISTA and anti-VISTA/anti-PD-L1 studies are eagerly awaited.
Material and methods

Ethics
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study. Ethical approval was obtained from the local ethical review board (D 453/10). All patient data were pseudonymized before study inclusion. All experimental work was complied with all mandatory laboratory health and safety procedures.
Study population
From the archive of the Institute of Pathology, University Hospital Kiel, we sought all patients who had undergone either total or partial gastrectomy for adenocarcinoma of the stomach or esophago-gastric junction between 1997 and 2009. The following patient characteristics were retrieved: type of surgery, age at diagnosis, gender, tumor size, tumor localization, tumor type, number of immune cells (e.g., lymphozytes, granulocytes, and macrophages) per 1 mm 2 in an intratumoral hot spot region, depth of invasion, residual tumor status, number of lymph nodes resected, and number of lymph nodes with metastases. Patients were included if an adenocarcinoma of the stomach or esophago-gastric junction was histologically confirmed.
Exclusion criteria were defined as (1) histology identified a tumor type other than adenocarcinoma, and (2) patients had undergone a perioperative chemo-or radio-therapy. Each resected specimen had undergone gross sectioning and histological examination by the trained and board certified surgical pathologists. Date of patient death was obtained from the Epidemiological Cancer Registry of the state of Schleswig-Holstein, Germany. Follow-up data of those patients who were still alive were retrieved from hospital records and general practitioners.
Histology
Tissue specimens were fixed in formalin and embedded in paraffin (FFPE). Deparaffinized sections were stained with hematoxylin and eosin. Histological re-examination of primary tissue sections was performed for all cases to ensure if inclusion criteria were met. Tumors were classified according to the Laur en classification 17 and re-examined by two surgical pathologists. pTNM-stage of all study patients was determined according to the 7th edition of the UICC guidelines. 18 
VISTA immunohistochemistry
FFPE tissue sections were pretreated in citrate buffer (pH 6) for antigen retrieval and incubated with hydrogen peroxide block and Ultra V Block (both Thermo Scientific, Braunschweig, Germany) to avoid unspecific reactions. Immunostaining was performed using a rabbit monoclonal anti-VISTA antibody (dilution 1:500, clone D1L2G, Cell Signaling, Danvers, USA) that recognizes endogenous levels of total VISTA protein. For visualization, the ImmPRESS-HRP-Universal-Antibody Polymer and the NovaRED substrate kit (both VectorLabs, Peterborough, United Kingdom) were applied. Counterstaining was done with hematoxylin (Dr. K. Hollborn & S€ ohne GmbH and Co KG; Leipzig, Germany). 
Evaluation of immunostaining
Assessment of phenotypic and genotypic characteristics of the study cohort
The H. pylori-, Her2/neu-, MET-, EBV-, MSI-, PD-L1-and PD-1-status as well as the KRAS-, PIK3CA-, RHOA-, and GNASgenotype was assessed as described previously.
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Study design
Whole tissue sections from GCs and corresponding liver metastases were stained with an antibody directed against VISTA. The staining results were correlated with clinico-pathological and survival data.
Statistical analysis
Statistical analyses were done using SPSS 20.0 (IBM Corporation, New York, USA). VISTA expressions within the different tumor components (tumor cells, immune cells and endothelial cells) were first examined as raw score values and then dichotomized by the median into "negative" and "positive" (tumor cells, endothelial cells) and "low" and "high" (immune cells), respectively. Cross tabulations of clinical data and marker expressions were tested for independence using Fisher's exact test. For cross tabulations of nominal variables having more than two categories and significant associations according to Fisher's exact test, an additional pairwise Fisher's exact test was performed. The correlation between the number of VISTA-positive immune cells evaluated by two different methods (positive immune cells per mm 2 and per 200 immune cells) was calculated by Pearson correlation (r). An r value of ¡1 indicated a perfect negative linear correlation, and an r value of 1 indicated a perfect positive linear correlation. The correlation between VISTA expression in GCs and corresponding metastases was calculated by using Cohen's kappa. A kappa value of 0.20 was considered to be poor, of 0.21-0.40 to be fair, of 0.41-0.60 to be moderate, of 0.61-0.80 to be good and of 0.81-1.00 to be very good. Median overall and tumor-specific survival were calculated using the Kaplan-Meier method. Log-rank test was used to determine significance of differences between survival curves. p-values < 0.05 were considered as statistically significant. False discovery rate of associations between clinical variables and biomarkers was controlled by applying the explorative Simes (BenjaminiHochberg) procedure. 24 All p-values are given unadjusted, but those having lost significance under the explorative Simes procedure are marked appropriately.
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